Advanced Search

Oncology & Hematology Coding Alert

HCPCS Q2048 or J9002 in 2013? Doxil Coding Changes Again in the New Year

Published on Tue Dec 04, 2012

Plus: See what’s different for Erwinaze, Adcetris, mitomycin, and more.   Other specialties may be reeling from CPT® 2013 changes, but for oncology and hematology, HCPCS is where the action is. Factor these medication supply code updates into your coding to start your New Year off on the right foot.   Add Another Chapter to the Doxil Story   Doxil coding saw quite a few changes in July 2012, and the saga continues for HCPCS 2013, effective January 1. The updated code set deletes both J9001 (Injection, doxorubicin hydrochloride, all lipid formulations, 10 mg) and the temporary code added in July, Q2048 (Injection, doxorubicin hydrochloride, liposomal, Doxil, 10 mg).   In place of Q2048, HCPCS 2013 adds J9002 (Injection, doxorubicin hydrochloride, liposomal, Doxil, 10 mg).   Note that Q2049 (Injection, doxorubicin hydrochloride, liposomal, imported Lipodox, 10 mg) will still be valid in 2013 for imported Lipodox, which has been used [...]
You’ve reached your limit of free articles. Already a subscriber? Log in.
Not a subscriber? Subscribe today to continue reading this article. Plus, you’ll get:
  • Simple explanations of current healthcare regulations and payer programs
  • Real-world reporting scenarios solved by our expert coders
  • Industry news, such as MAC and RAC activities, the OIG Work Plan, and CERT reports
  • Instant access to every article ever published in Revenue Cycle Insider
  • 6 annual AAPC-approved CEUs
  • The latest updates for CPT®, ICD-10-CM, HCPCS Level II, NCCI edits, modifiers, compliance, technology, practice management, and more

Other Articles in this issue of

Oncology & Hematology Coding Alert

View All